New York Valves 2026 — Dr Firas Zahr (Oregon Health & Science University, Portland, OR, US) discusses the rapidly evolving structural heart landscape, highlighting new transcatheter valve technologies and practice-changing data. Recently approved devices for aortic and mitral valve disease, alongside ongoing pivotal trials in the aortic, mitral and tricuspid spaces, are expanding treatment options and enabling minimally invasive solutions for patients previously considered untreatable.

Dr Zahr also explores the growing role of registry and real-world data in refining patient selection and guiding Heart Team decisions, particularly with emerging therapies such as transcatheter mitral valve replacement (TMVR). As innovation accelerates, he emphasises the importance of critically evaluating evidence while anticipating upcoming trial results that will shape earlier intervention strategies and broaden treatment to lower-risk populations.

Recorded on-site at New York Valves 2026.
Editors: Mirjam Boros, Jordan Rance
Videographer: Dan Brent
Support: This is an independent interview produced by Radcliffe Cardiology.